MTSR
Metsera Inc (MTSR)
Healthcare • NASDAQ • $70.50-0.35%
- Symbol
- MTSR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $70.50
- Daily Change
- -0.35%
- Market Cap
- $7.43B
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $83.86
- 52W Low
- $12.30
- Analyst Target
- $57.00
- Dividend Yield
- N/A
- Beta
- N/A
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.
Company websiteResearch MTSR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.